Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12937376 | 1.00 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL15492500 | 0.90 | DPP4 (0.82) | DPP4CYP3A4 | |
| SCHEMBL14899002 | 0.90 | DPP4 (0.82) | DPP4CYP3A4 | |
| SCHEMBL14899610 | 0.86 | DPP4 (0.81) | DPP4CYP3A4 | |
| SCHEMBL12937403 | 0.86 | DPP4 (0.81) | DPP4CYP3A4 | |
| SCHEMBL14899028 | 0.86 | DPP4 (0.81) | DPP4CYP3A4 | |
| SCHEMBL14898985 | 0.84 | DPP4 (0.72) | DPP4CYP3A4 | |
| SCHEMBL14216710 | 0.84 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL26688738 | 0.84 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL14899080 | 0.83 | DPP4 (0.78) | DPP4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2995615-A1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2016-03-16 | — | — | EP | disclosed |
| US-8980322-B2 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| EP-1559710-B1 | Dipeptidyl peptidase IV inhibitors based on cyclopropyl-fused pyrrolidine, process for their preparation and their use | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| EP-2191824-B1 | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-1671649-B1 | Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure | TAKEDA PHARMACEUTICAL (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20110086096-A1 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION | KOWALSKI JAMES | 2011-04-14 | — | — | US | disclosed |
| EP-2191824-A1 | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | Novartis AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20100021539-A1 | Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation | KOWALSKI JAMES | 2010-01-28 | — | — | US | disclosed |
| EP-1898904-B1 | MODIFIED RELEASE 1-[(3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL]-PYRROLIDINE-2(S)-CARBONITRILE FORMULATION | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20070072810-A1 | Agent for treating diabetes | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-20060177509-A1 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1671649-A1 | REMEDY FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-20060039974-A1 | Sustained release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1607088-A1 | CONTROLLED RELEASE COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| EP-1537880-A1 | SUSTAINED RELEASE PREPARATION | Takeda Pharmaceutical Company Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086096-A1 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION | MAST1, CACNG1, CMA1 | DPP4 267/4885CYP3A4 991/4885 |
| US-20070072810-A1 | Agent for treating diabetes | IAPP, DPP4, GLP1R | DPP4 2/4885CYP3A4 2599/4885 |
| US-20060039974-A1 | Sustained release preparation | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 190/4885 |
| US-20100021539-A1 | Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation | MAST1, CMA1, SUCNR1 | DPP4 195/4885CYP3A4 879/4885 |
| US-20060177509-A1 | Controlled release composition | ATP6AP1, NSF, ATP6V1G1 | DPP4 2445/4885CYP3A4 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.